Email this article TWO PROGRAMS OF CHEMOTHERAPY IN COMBINATION WITH BEVACIZUMAB IN THE TREATMENT OF DISSEMINATED COLORECTAL CANCER
- Authors: Zharkova O.V.1, Karaseva V.V.2, Khailenko V.A.2, Mironova E.B.3, Feoktistova P.S.4, Vyalova K.V.1, Kolesnikov Y.M.1
-
Affiliations:
- Regional Clinical Oncology Dispensary, Kemerovo
- N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
- Clinical Hospital Eighty-One, Federal Biomedical Agency of Russia, Seversk
- Nizhnevartovsk Oncology Dispensary, Khanty-Mansiysk Autonomous Oncology Dispensary
- Issue: Vol 2, No 1 (2013)
- Pages: 54-57
- Section: ORIGINAL REPORTS
- Published: 02.03.2015
- URL: https://onco-surgery.info/jour/article/view/108
- DOI: https://doi.org/10.17650/2220-3478-2013-0-1-54-57
- ID: 108
Cite item
Full Text
Abstract
The efficiency of 2 programs of chemotherapy in the treatment of 46 patients with disseminated colorectal cancer. The program of chemo-therapy of oxaliplatin + capecitabine (ОХА/САР), established authors, with bevacizumab (BEV) showed the best results compared with oxaliplatin + 5-fluorouracyl + leukovorin (ОХА/5-FU/LV) with bevacizumab. The overall efficiency OXA/5-FU/LV/BEV amounted to 40.91 ± 8.6 %, 4.54 ± 5.1 % of total regressions. The overall effect of therapy in the OXA/CAP/BEV amounted to 45.83 ± 8.6 %, full regression was achieved in 4 patients, which amounted to 16.66 ± 5.6 %. The median time to progression in the first group of patients was 8.3 months, in the second – 9.8 months. Clinical application of involving bevacizumab in combination with different modes of chemotherapy in patients with disseminated colorectal cancer is acceptable and manageable toxicity that doesn't require reduction of doses.
About the authors
O. V. Zharkova
Regional Clinical Oncology Dispensary, Kemerovo
Author for correspondence.
Email: Olga.zh1212@gmail.com
Russian Federation
V. V. Karaseva
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Email: Olga.zh1212@gmail.com
Russian Federation
V. A. Khailenko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
Email: fake@neicon.ru
Russian Federation
E. B. Mironova
Clinical Hospital Eighty-One, Federal Biomedical Agency of Russia, Seversk
Email: Olga.zh1212@gmail.com
Russian Federation
P. S. Feoktistova
Nizhnevartovsk Oncology Dispensary, Khanty-Mansiysk Autonomous Oncology Dispensary
Email: Olga.zh1212@gmail.com
Russian Federation
K. V. Vyalova
Regional Clinical Oncology Dispensary, Kemerovo
Email: Olga.zh1212@gmail.com
Russian Federation
Ya. M. Kolesnikov
Regional Clinical Oncology Dispensary, Kemerovo
Email: Olga.zh1212@gmail.com
Russian Federation
References
Supplementary files
